▁Ad 10.375
van 9.5234375
c 3.826171875
ements 0.81201171875
▁in 4.0703125
▁the 2.0
▁treatment 7.3671875
▁of 0.255615234375
▁mel 8.046875
an 1.31640625
oma 0.1312255859375
▁have 3.62890625
▁greatly 4.15625
▁improved 0.95263671875
▁the 2.234375
▁potential 5.79296875
▁for 1.701171875
▁long 5.9375
- 0.65478515625
term 0.25048828125
▁rem 5.30859375
ission 0.494873046875
, 2.841796875
▁particularly 3.908203125
▁with 3.033203125
▁the 1.8447265625
▁use 3.91015625
▁of 0.072021484375
▁imm 5.4609375
une 2.32421875
▁check 6.35546875
point 1.1533203125
▁in 1.7626953125
hib 0.0347900390625
itors 1.8056640625
▁and 2.669921875
▁adj 5.3671875
uv 1.1484375
ant 2.033203125
▁ther 2.73828125
ap 0.77978515625
ies 0.03704833984375
. 1.279296875
▁These 3.984375
▁treat 3.763671875
ments 0.007354736328125
▁have 1.2197265625
▁shown 3.92578125
▁prom 3.212890625
ising 0.00240325927734375
▁results 0.72412109375
▁in 1.2294921875
▁impro 3.767578125
ving 0.0006823539733886719
▁surv 3.740234375
ival 0.0091705322265625
▁rates 1.130859375
▁for 1.9638671875
▁patients 1.24609375
▁at 5.40234375
▁different 6.23046875
▁stages 0.517578125
▁of 0.342529296875
▁mel 1.1953125
an 0.0221405029296875
oma 0.055267333984375
. 1.0654296875
▁By 6.6640625
▁expl 5.95703125
oring 0.00449371337890625
▁the 0.9462890625
▁case 6.88671875
▁of 1.0556640625
▁Mr 5.98828125
. 0.274658203125
▁B 4.19140625
, 1.8662109375
▁we 1.0947265625
▁can 1.845703125
▁del 5.58203125
ve 0.54541015625
▁into 0.462890625
▁the 0.475341796875
▁imp 5.5390625
lications 0.109375
▁of 0.2293701171875
▁these 1.8251953125
▁treat 1.5810546875
ments 0.0007100105285644531
▁and 1.3369140625
▁discuss 3.501953125
▁the 1.0859375
▁evidence 6.93359375
▁supporting 2.39453125
▁their 0.77294921875
▁effic 1.8603515625
acy 0.0029430389404296875
. 0.64697265625
<0x0A> 0.44384765625
M 2.578125
el 0.164794921875
an 0.0023593902587890625
oma 0.02301025390625
▁is 0.52880859375
▁a 0.48291015625
▁type 1.3837890625
▁of 0.0015611648559570312
▁skin 0.59521484375
▁cancer 0.00945281982421875
▁that 0.482666015625
▁ar 3.095703125
ises 0.00052642822265625
▁from 0.45458984375
▁the 1.1513671875
▁p 2.90625
ig 0.00070953369140625
ment 0.038665771484375
- 0.7646484375
produ 0.097412109375
cing 0.0005898475646972656
▁cells 0.252197265625
, 3.68359375
▁known 2.7109375
▁as 0.0059814453125
▁mel 0.023956298828125
an 0.009796142578125
ocy 0.0028362274169921875
tes 0.00234222412109375
. 1.287109375
▁It 1.87890625
▁is 0.5537109375
▁not 5.37890625
orious 3.13671875
▁for 0.111328125
▁its 0.5986328125
▁ag 2.5234375
gress 0.00377655029296875
ive 0.5732421875
▁nature 0.73193359375
▁and 0.78955078125
▁potential 4.78125
▁to 1.47265625
▁met 1.693359375
ast 4.303455352783203e-05
as 0.007717132568359375
ize 0.01508331298828125
. 1.9736328125
▁However 4.41796875
, 0.0016145706176757812
▁with 3.21875
▁the 0.9716796875
▁advent 2.7734375
▁of 0.0183563232421875
▁imm 2.10546875
une 1.3916015625
▁check 0.03912353515625
point 0.00604248046875
▁in 0.07647705078125
hib 0.00067901611328125
itors 0.1964111328125
, 0.9384765625
▁such 3.845703125
▁as 0.04638671875
▁p 1.4111328125
emb 0.0026187896728515625
rol 0.0017290115356445312
iz 0.002231597900390625
um 0.0010509490966796875
ab 0.0003197193145751953
▁and 1.33203125
▁n 0.126953125
iv 0.0016193389892578125
ol 0.0004742145538330078
um 0.0010471343994140625
ab 0.0007090568542480469
, 0.0692138671875
▁remarkable 8.3046875
▁adv 2.234375
anc 0.57177734375
ements 2.205371856689453e-05
▁have 0.363037109375
▁been 0.053192138671875
▁made 0.2279052734375
▁in 0.2093505859375
▁the 0.650390625
▁treatment 0.271484375
▁of 0.1014404296875
▁advanced 3.521484375
▁mel 0.330078125
an 0.0002608299255371094
oma 0.060333251953125
. 0.394775390625
<0x0A> 1.3037109375
Im 3.61328125
m 0.2359619140625
une 0.03857421875
▁check 0.187255859375
point 0.034027099609375
▁in 0.037994384765625
hib 0.0008778572082519531
itors 0.05670166015625
▁work 2.734375
▁by 0.1680908203125
▁en 5.88671875
han 0.2296142578125
cing 1.3709068298339844e-05
▁the 0.2342529296875
▁body 1.681640625
' 0.005645751953125
s 0.00028324127197265625
▁imm 0.63720703125
une 0.0193023681640625
▁response 1.0615234375
▁against 1.4912109375
▁cancer 1.1572265625
▁cells 0.476318359375
. 0.58984375
▁They 2.037109375
▁in 4.04296875
hib 0.0166015625
it 0.0017137527465820312
▁the 0.77880859375
▁activity 2.486328125
▁of 0.01065826416015625
▁prote 3.36328125
ins 0.0007672309875488281
▁called 1.115234375
▁imm 1.6171875
une 0.041107177734375
▁check 0.0096588134765625
points 0.1280517578125
, 0.6171875
▁which 0.70703125
▁restrict 5.75390625
▁the 0.3603515625
▁imm 1.3828125
une 0.003696441650390625
▁system 0.2061767578125
' 0.6005859375
s 0.0003306865692138672
▁ability 0.4423828125
▁to 0.0015325546264648438
▁recognize 1.509765625
▁and 0.5732421875
▁target 3.388671875
▁cancer 0.492919921875
▁cells 0.1221923828125
. 0.123046875
▁By 2.447265625
▁blocking 2.353515625
▁these 0.548828125
▁check 1.2880859375
points 0.051666259765625
, 0.049163818359375
▁the 1.3037109375
▁imm 0.3623046875
une 0.003978729248046875
▁system 0.109375
▁is 1.00390625
▁un 5.90625
le 0.1383056640625
ashed 0.000995635986328125
▁to 0.47216796875
▁attack 1.2587890625
▁and 1.31640625
▁destroy 0.7021484375
▁the 1.9560546875
▁tum 1.736328125
or 0.09710693359375
▁cells 0.76318359375
. 0.26611328125
<0x0A> 0.66552734375
In 2.64453125
▁the 1.8447265625
▁case 0.7958984375
▁of 0.0147552490234375
▁Mr 0.697265625
. 0.00962066650390625
▁B 0.0129852294921875
, 0.05706787109375
▁a 2.3828125
▁ 0.7734375
5 1.3896484375
5 2.169921875
- 0.039886474609375
year 0.00238800048828125
- 0.0338134765625
old 0.0010099411010742188
▁mel 4.73046875
an 0.0003647804260253906
oma 0.007450103759765625
▁patient 0.261962890625
▁diagn 3.65625
osed 0.00028228759765625
▁with 0.245849609375
▁stage 1.1298828125
▁IV 0.6044921875
▁met 1.796875
ast 0.00286865234375
atic 0.0311431884765625
▁mel 0.132568359375
an 0.0002465248107910156
oma 0.0012483596801757812
, 0.8974609375
▁treatment 3.318359375
▁with 0.568359375
▁a 3.80078125
▁combination 1.091796875
▁of 0.0635986328125
▁imm 2.015625
une 0.04718017578125
▁check 0.026947021484375
point 0.00691986083984375
▁in 0.01337432861328125
hib 0.0004949569702148438
itors 0.09423828125
▁led 2.388671875
▁to 0.0161895751953125
▁a 0.8515625
▁significant 1.603515625
▁improvement 0.7783203125
▁in 0.05352783203125
▁his 0.82861328125
▁pro 2.470703125
gn 0.53125
osis 0.01395416259765625
. 0.3212890625
▁Studies 9.0
▁have 0.423095703125
▁shown 0.325927734375
▁that 0.10308837890625
▁the 1.8662109375
▁use 1.8564453125
▁of 0.000988006591796875
▁p 2.458984375
emb 0.0046539306640625
rol 0.00012886524200439453
iz 0.0012903213500976562
um 0.0010900497436523438
ab 0.00010597705841064453
▁and 1.0927734375
▁n 0.06646728515625
iv 0.002635955810546875
ol 0.00040435791015625
um 0.0012311935424804688
ab 0.0003783702850341797
▁in 2.16015625
▁patients 2.064453125
▁with 0.1431884765625
▁advanced 1.1240234375
▁mel 0.18115234375
an 0.0001277923583984375
oma 0.0059051513671875
▁can 2.4296875
▁result 2.533203125
▁in 0.0008921623229980469
▁dur 4.5625
able 0.00336456298828125
▁responses 0.6494140625
▁and 1.291015625
▁long 2.619140625
- 0.049835205078125
term 0.04644775390625
▁rem 1.6396484375
ission 0.65478515625
. 0.6123046875
▁In 2.775390625
▁a 3.26953125
▁study 1.3486328125
▁by 2.55859375
▁Robert 6.84375
▁et 9.015625
▁al 0.0224151611328125
., 0.650390625
▁the 1.7685546875
▁overall 2.974609375
▁response 0.412109375
▁rate 0.09698486328125
▁to 3.154296875
▁p 1.16015625
emb 0.00592803955078125
rol 0.00014793872833251953
iz 0.0009474754333496094
um 0.0012502670288085938
ab 8.726119995117188e-05
▁was 1.0625
▁ 0.1656494140625
3 1.88671875
3 2.158203125
%, 1.685546875
▁with 1.00390625
▁a 0.8662109375
▁median 0.60791015625
▁overall 1.4765625
▁surv 0.0594482421875
ival 0.00020241737365722656
▁of 0.300048828125
▁ 0.09912109375
2 1.6298828125
3 2.318359375
▁months 0.65869140625
, 2.671875
▁providing 5.8984375
▁hope 3.01171875
▁for 0.29248046875
▁patients 1.560546875
▁like 5.01171875
▁Mr 0.031494140625
. 0.006038665771484375
▁B 0.004383087158203125
. 0.5029296875
<0x0A> 0.44287109375
Ad 5.23828125
j 2.05078125
uv 0.0067596435546875
ant 0.0010051727294921875
▁ther 0.3994140625
ap 0.407958984375
ies 0.000301361083984375
, 2.361328125
▁which 2.255859375
▁are 0.5380859375
▁admin 1.4296875
ister 0.0004394054412841797
ed 0.00011420249938964844
▁alongside 5.6484375
▁primary 4.08203125
▁treat 3.115234375
ments 0.00013434886932373047
, 0.5576171875
▁have 2.419921875
▁also 1.2255859375
▁played 3.04296875
▁a 0.401611328125
▁cru 2.2265625
cial 0.00021541118621826172
▁role 0.0164947509765625
▁in 0.00974273681640625
▁impro 0.77587890625
ving 1.3113021850585938e-05
▁surv 1.6201171875
ival 0.00843048095703125
▁rates 0.3203125
▁in 1.9375
▁patients 1.017578125
▁with 0.25439453125
▁mel 0.6552734375
an 0.00013959407806396484
oma 0.0032253265380859375
. 0.0836181640625
▁In 2.62890625
▁particular 2.748046875
, 0.0020618438720703125
▁target 5.04296875
ed 0.050994873046875
▁ther 0.31982421875
ap 0.1705322265625
ies 4.3272972106933594e-05
▁and 2.431640625
▁combination 5.36328125
▁ther 0.67041015625
ap 0.038970947265625
ies 2.300739288330078e-05
▁have 0.59716796875
▁shown 1.8095703125
▁prom 1.4462890625
ising 0.00026798248291015625
▁out 2.572265625
comes 0.0007867813110351562
. 2.169921875
▁Target 2.546875
ed 0.014068603515625
▁ther 0.07220458984375
ap 0.12054443359375
ies 3.814697265625e-05
, 1.2998046875
▁such 0.425048828125
▁as 0.0022106170654296875
▁B 4.1484375
RA 0.181396484375
F 0.00872039794921875
▁and 1.873046875
▁ME 0.60986328125
K 0.001171112060546875
▁in 0.032867431640625
hib 0.0002605915069580078
itors 0.025665283203125
, 0.075927734375
▁specifically 4.9609375
▁target 0.74951171875
▁the 1.3046875
▁gen 2.271484375
etic 0.76220703125
▁mut 1.2578125
ations 0.1527099609375
▁present 3.119140625
▁in 0.02203369140625
▁mel 0.81689453125
an 6.711483001708984e-05
oma 0.10772705078125
▁cells 0.828125
. 0.544921875
▁These 2.740234375
▁in 2.146484375
hib 0.00275421142578125
itors 0.1541748046875
▁have 1.2841796875
▁been 1.1259765625
▁successful 4.921875
▁in 0.1737060546875
▁patients 5.3984375
▁with 0.32763671875
▁B 1.14453125
RA 0.0001817941665649414
F 0.0010061264038085938
▁gene 5.8671875
▁mut 0.1943359375
ations 0.098876953125
, 0.84716796875
▁including 3.177734375
▁Mr 1.498046875
. 0.006771087646484375
▁B 0.0467529296875
, 1.4833984375
▁leading 3.28125
▁to 0.006099700927734375
▁higher 7.28125
▁response 1.296875
▁rates 0.043212890625
▁and 0.5400390625
▁longer 1.2880859375
▁pro 3.2890625
gression 0.0063323974609375
- 0.0172271728515625
free 0.0009975433349609375
▁surv 0.0648193359375
ival 0.0225372314453125
. 0.5244140625
<0x0A> 0.8798828125
F 4.87109375
ur 0.029937744140625
ther 0.00011909008026123047
more 0.1507568359375
, 0.0003552436828613281
▁combination 0.38525390625
▁ther 0.07623291015625
ap 0.024139404296875
ies 1.1563301086425781e-05
▁that 4.140625
▁combine 1.041015625
▁imm 0.9853515625
une 0.1241455078125
▁check 0.03143310546875
point 0.00844573974609375
▁in 0.0118255615234375
hib 0.00014221668243408203
itors 0.0173187255859375
▁with 0.4794921875
▁target 1.2587890625
ed 0.0018377304077148438
▁ther 0.1102294921875
ap 0.036041259765625
ies 1.6927719116210938e-05
▁have 0.87548828125
▁shown 1.185546875
▁even 4.7109375
▁more 1.638671875
▁impress 1.8310546875
ive 0.0002532005310058594
▁results 0.48681640625
. 0.381591796875
▁For 2.037109375
▁instance 1.2841796875
, 0.0008115768432617188
▁the 1.703125
▁combination 0.94677734375
▁of 0.083984375
▁d 4.60546875
ab 0.1685791015625
raf 0.03240966796875
en 0.0024662017822265625
ib 0.0006380081176757812
▁and 0.405029296875
▁tram 0.0295562744140625
et 0.00438690185546875
in 0.0023326873779296875
ib 9.250640869140625e-05
, 1.7060546875
▁B 5.75390625
RA 0.0111541748046875
F 0.00510406494140625
▁and 1.2119140625
▁ME 0.0321044921875
K 4.3272972106933594e-05
▁in 0.0170135498046875
hib 0.0005822181701660156
itors 0.0185394287109375
▁respectively 3.564453125
, 0.00966644287109375
▁with 6.37109375
▁imm 2.65234375
un 3.607421875
other 0.0172576904296875
apy 0.12017822265625
▁has 1.0732421875
▁demonstrated 2.91015625
▁significant 3.044921875
▁improvements 1.720703125
▁in 0.0740966796875
▁overall 2.431640625
▁response 1.2734375
▁rates 0.460693359375
▁and 0.611328125
▁pro 0.79052734375
gression 0.0020656585693359375
- 0.0301361083984375
free 0.001033782958984375
▁surv 0.004535675048828125
ival 0.00223541259765625
. 0.48974609375
▁This 2.384765625
▁combination 0.407958984375
▁ther 1.322265625
apy 0.0015535354614257812
▁has 0.51953125
▁been 1.0693359375
▁approved 4.2734375
▁by 0.495361328125
▁the 0.078857421875
▁F 0.6728515625
DA 0.0003859996795654297
▁for 0.630859375
▁the 0.93212890625
▁treatment 0.057037353515625
▁of 0.003116607666015625
▁mel 2.1484375
an 3.9577484130859375e-05
oma 0.008209228515625
▁patients 1.2099609375
▁with 0.363037109375
▁B 0.34765625
RA 0.00021576881408691406
F 0.0007600784301757812
▁mut 1.5048828125
ations 0.08111572265625
. 0.8212890625
<0x0A> 0.23779296875
Over 2.81640625
all 0.01397705078125
, 0.00806427001953125
▁adv 4.9453125
anc 0.294677734375
ements 2.682209014892578e-05
▁in 0.056182861328125
▁mel 2.02734375
an 0.00010633468627929688
oma 0.0014753341674804688
▁treatment 0.492919921875
, 3.58984375
▁particularly 1.203125
▁the 1.728515625
▁use 0.27880859375
▁of 0.0018444061279296875
▁imm 0.1900634765625
une 0.0902099609375
▁check 0.0081024169921875
point 0.00342559814453125
▁in 0.002994537353515625
hib 0.00010025501251220703
itors 0.00812530517578125
▁and 1.3720703125
▁adj 0.34130859375
uv 0.0030193328857421875
ant 0.0013418197631835938
▁ther 0.0216522216796875
ap 0.01358795166015625
ies 1.2636184692382812e-05
, 0.103759765625
▁have 0.1607666015625
▁significantly 2.734375
▁increased 3.7265625
▁the 0.7099609375
▁potential 4.046875
▁for 0.302734375
▁long 0.5712890625
- 0.0164031982421875
term 0.0017938613891601562
▁rem 0.4794921875
ission 0.0163116455078125
▁and 0.72607421875
▁improved 1.291015625
▁surv 0.60009765625
ival 0.00307464599609375
▁rates 0.254150390625
. 0.87939453125
▁These 1.7978515625
▁treat 0.86865234375
ments 7.271766662597656e-05
▁have 0.30859375
▁shown 1.453125
▁prom 0.62109375
ising 2.9087066650390625e-05
▁results 0.396484375
▁in 0.3369140625
▁patients 2.486328125
▁at 0.845703125
▁different 0.087646484375
▁stages 0.007091522216796875
▁of 0.0107574462890625
▁mel 0.10028076171875
an 3.802776336669922e-05
oma 0.001369476318359375
, 0.60595703125
▁both 5.40625
▁in 0.9169921875
▁terms 0.92529296875
▁of 0.0003733634948730469
▁improved 3.69921875
▁overall 1.916015625
▁response 1.69140625
▁rates 0.12139892578125
▁and 0.083984375
▁increased 4.53515625
▁overall 4.05078125
▁surv 0.07489013671875
ival 0.005718231201171875
. 0.2340087890625
▁The 3.07421875
▁case 4.1796875
▁of 0.0228729248046875
▁Mr 0.008544921875
. 0.00446319580078125
▁B 0.0031528472900390625
▁exempl 3.05078125
ifies 0.01087188720703125
▁the 0.3984375
▁effic 3.61328125
acy 6.449222564697266e-05
▁of 0.135986328125
▁these 0.6259765625
▁treat 0.2264404296875
ments 4.792213439941406e-05
, 1.50390625
▁with 2.892578125
▁his 1.5673828125
▁favor 6.4453125
able 0.0025806427001953125
▁response 1.2763671875
▁to 0.66552734375
▁imm 0.99560546875
une 0.1824951171875
▁check 0.00988006591796875
point 0.0020771026611328125
▁in 0.00673675537109375
hib 0.00011479854583740234
itors 0.06707763671875
▁and 0.91015625
▁target 6.15234375
ed 0.00275421142578125
▁ther 0.033782958984375
ap 0.056793212890625
ies 1.0013580322265625e-05
. 1.626953125
▁Cont 8.9609375
in 0.181396484375
ued 0.007354736328125
▁research 0.405517578125
▁and 0.92236328125
▁adv 2.130859375
anc 0.1641845703125
ements 4.7326087951660156e-05
▁in 0.34619140625
▁this 2.873046875
▁field 0.472900390625
▁offer 5.91796875
▁hope 0.337158203125
▁for 0.1563720703125
▁mel 3.384765625
an 0.00013244152069091797
oma 0.004695892333984375
▁patients 0.016021728515625
, 2.03515625
▁as 2.625
▁these 1.3544921875
▁treat 0.29345703125
ments 2.6345252990722656e-05
▁p 8.5546875
ave 0.00533294677734375
▁the 0.0246429443359375
▁way 0.01444244384765625
▁for 0.146728515625
▁better 2.923828125
▁out 0.53857421875
comes 0.0036640167236328125
▁and 0.8544921875
▁potentially 5.265625
▁higher 5.98046875
▁c 1.31640625
ure 0.265625
▁rates 0.00470733642578125
. 0.25439453125
